Document Detail

Amlodipine seems to be superior to valsartan in decreasing microalbuminuria in newly diagnosed hypertensive patients: a novel effect to be explained with hyperfiltration?
MedLine Citation:
PMID:  23297711     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Microalbuminuria (MA) is common in hypertensive population and is a marker for endothelial dysfunction and a predictor of increased cardiovascular risk. A great body of data shows the importance of MA as a strong predictor of renal and cardiovascular disease (CVD) risk in hypertensive population.
AIM: In this study, we aimed to compare the anti-albuminuric effects of an angiotensin II receptor antagonist, valsartan, with a calcium channel blocker, amlodipine, in newly diagnosed hypertensive patients.
MATERIAL AND METHODS: Totally, 20 patients were recruited into the study. Patients were randomized to one of the following intervention protocols: An (a) angiotensin II receptor blocker (valsartan, 80-320 mg/day) or (b) calcium channel blocker (amlodipine, 5-10 mg/day), for 12 weeks immediately after baseline measurements. Ten patients were randomized into valsartan group and 10 patients into the amlodipine group. Twenty-four-hour urinary albumin excretion (UAE) levels of the patient groups were measured before treatment and on the 12th week.
RESULTS: Patients of the two groups were matched for age and body mass index. In the amlodipine group, baseline urine microalbumin levels were higher compared to valsartan group, although the difference was not statistically significant (p = 0.082). At the 12th week, there was a significant decrease in urine microalbumin levels in the amlodipine group, but no significant change was observed in the valsartan group.
CONCLUSION: Amlodipine seems to be superior to valsartan in decreasing UAE. To reduce cardiovascular risks, endothelial dysfunction, and microinflammation, these factors are taken into consideration while prescribing antihypertensive drugs in hypertensive patients.
Seyit Ahmet Ay; Mustafa Cakar; Murat Karaman; Sevket Balta; Sait Demirkol; Murat Unlu; Omer Kurt; Battal Altun; Muharrem Akhan; Erol Arslan; Bayram Koc; Fatih Bulucu
Publication Detail:
Type:  Comparative Study; Journal Article; Randomized Controlled Trial     Date:  2013-01-09
Journal Detail:
Title:  Renal failure     Volume:  35     ISSN:  1525-6049     ISO Abbreviation:  Ren Fail     Publication Date:  2013  
Date Detail:
Created Date:  2013-03-12     Completed Date:  2013-12-16     Revised Date:  2014-02-06    
Medline Journal Info:
Nlm Unique ID:  8701128     Medline TA:  Ren Fail     Country:  England    
Other Details:
Languages:  eng     Pagination:  357-60     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Albuminuria / drug therapy*,  etiology
Amlodipine / pharmacology,  therapeutic use*
Angiotensin II Type 1 Receptor Blockers / pharmacology,  therapeutic use*
Calcium Channel Blockers / pharmacology,  therapeutic use*
Hypertension / complications,  drug therapy*
Middle Aged
Tetrazoles / pharmacology,  therapeutic use*
Valine / analogs & derivatives*,  pharmacology,  therapeutic use
Reg. No./Substance:
0/Angiotensin II Type 1 Receptor Blockers; 0/Calcium Channel Blockers; 0/Tetrazoles; 137862-53-4/valsartan; 1J444QC288/Amlodipine; HG18B9YRS7/Valine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Camera-port Site Metastasis of a Renal Cell Carcinoma after Robot-Assisted Partial Nephrectomy.
Next Document:  Composition and Evaluation of the Anti-Inflammatory and Anticancer Activities of the Essential Oil f...